J. Goldman & CO LP Otonomy, Inc. Transaction History

J. Goldman & CO LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$1.72 - $2.51 $232,200 - $338,850	135,000 New	135,000 $281,000
Q3 2021 Nov 15, 2021	SELL	$1.22 - $2.2 $324,090 - $584,425	-265,648 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$2.06 - $2.67 $148,015 - $191,844	-71,852 Reduced 21.29%	265,648 $592,000
Q1 2021 May 17, 2021	BUY	$2.49 - $6.23 $174,840 - $437,451	70,217 Added 26.27%	337,500 $861,000
Q4 2020 Feb 16, 2021	SELL	$3.48 - $6.47 $2.29 Million - $4.25 Million	-657,362 Reduced 71.09%	267,283 $1.73 Million
Q3 2020 Nov 16, 2020	BUY	$3.16 - $4.36 $1.31 Million - $1.81 Million	415,481 Added 81.6%	924,645 $3.75 Million
Q2 2020 Aug 14, 2020	SELL	$1.87 - $3.84 $483,671 - $993,208	-258,648 Reduced 33.69%	509,164 $1.84 Million
Q1 2020 May 15, 2020	BUY	$1.58 - $4.06 $1.21 Million - $3.12 Million	767,812 New	767,812 $1.51 Million
Q2 2018 Aug 14, 2018	SELL	$3.7 - $4.75 $577,200 - $741,000	-156,000 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$4.05 - $6.1 $473,850 - $713,700	-117,000 Reduced 42.86%	156,000 $655,000
Q4 2017 Feb 14, 2018	BUY	$2.8 - $5.55 $764,400 - $1.52 Million	273,000	273,000 $1.52 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.